This site is intended for UK Healthcare Professionals only

UK/FLY/2023/2537 V3 | October 2024

Prescribing information and adverse event reporting statement can be found in the footer
Back

A 3-in-1 synergistic action to help maximise the eradication of H.pylori1-3

In combination with omeprazole, PYLERA® is indicated for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers1
“Antibiotic resistance is the most important factor in triple therapy failure4,5”
Bismuth containing quadruple therapy (PYLERA®) increases the susceptibility of clarithromycin and metronidazole-resistant H. pylori strains3,8
References
  1. Pylera SmPC. (Accessed October 2024).
  2. Malfertheiner P, et al. Lancet. 2011;377:905–13.
  3. Malfertheiner P, et al. Nat Rev Dis Prim. 2023;9:19.
  4. NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. Last updated October 2019.
  5. Malfertheiner P, et al. Gut. 2022;71:1724–1762.
  6. Savoldi A, et al. Gastroenterol. 2018;155(5):1372–1382.
  7. Flynn Pharma. Data on File Ref/PYL/DOF/3154. May 2024.
  8. Kateralis, P, et al. J Clin Gastroenterol. 2023;57:111–126.